Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below 200-Day Moving Average – Should You Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.33 and traded as low as $5.31. Karyopharm Therapeutics shares last traded at $5.45, with a volume of 118,422 shares.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on KPTI shares. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (down from $15.00) on shares of Karyopharm Therapeutics in a research note on Thursday, October 9th. Wall Street Zen upgraded Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, October 9th. Royal Bank Of Canada lowered their target price on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, November 17th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.40.

Karyopharm Therapeutics Stock Performance

The stock has a 50 day moving average price of $5.96 and a 200 day moving average price of $5.33. The company has a market capitalization of $94.63 million, a P/E ratio of -0.38 and a beta of 0.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The company had revenue of $44.04 million for the quarter, compared to analyst estimates of $39.56 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC bought a new stake in shares of Karyopharm Therapeutics in the third quarter valued at $164,000. Bridgeway Capital Management LLC purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth about $163,000. Bank of America Corp DE increased its holdings in Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after acquiring an additional 35,626 shares during the last quarter. Baird Financial Group Inc. bought a new stake in Karyopharm Therapeutics in the 2nd quarter valued at about $45,000. Finally, Silverback Asset Management LLC lifted its holdings in Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares during the last quarter. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).